Recent Updates
Recently added Catalysts

testosterone undecanoate

Phase 2

Hypogonadism | Small molecule | Endocrine |Merck & Company, Inc.|Last Updated: Apr 16, 2015

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment322

FDA Designations

No designations recorded

Clinical trial landscape

testosterone undecanoate · 1 trial · 2 indications

Phase 2 1
NCT00434824Effects of Andriol Testocaps in Symptomatic Late-Onset Hypogonadism (43203)Hypogonadism
COMPLETED322 Analytics
PHASE2COMPLETED
Effects of Andriol Testocaps in Symptomatic Late-Onset Hypogonadism (43203)
HypogonadismUnlock trial analytics

Study Endpoints

Primary Endpoints

Change from baseline on the total score of the AMS rating scale
Month 6

Secondary Endpoints

Effects on AMS rating scale, bone mineral density, bone markers, muscle and fat mass, muscle strength, hematocrit, endocrine parameters, PSA, IPSS and lipids
Month 12
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Arm 1ACTIVE_COMPARATOROral testosterone undecanoate (Andriol)
Arm 2PLACEBO_COMPARATORPlacebo

Interventions

NameTypeDescription
Oral testosterone undecanoate (Andriol)DRUGtreatment for 12 months with oral TU 80 mg/d, oral TU 160 mg/d or oral TU 240 mg/d in divided doses
PlaceboDRUGtreatment for 12 months with placebo in divided doses
Unlock Study Design Details

Eligibility Criteria

Age Range50 Years to N/A
SexMALE
Healthy VolunteersNo

Inclusion Criteria: * Subjects were at least 50 years of age * A body mass index (BMI) between 18 and 34 kg/m\^2 * Symptoms of androgen deficiency (as indicated by a positive Androgen Deficiency in Aging Males (ADAM) questionnaire) * Calculated free testosterone measurement of \<0.26 nmol/L in the ...

Unlock Eligibility Criteria

Frequently asked questions about testosterone undecanoate

What is testosterone undecanoate used for?

Testosterone undecanoate is used for hypogonadism, a condition in which the body does not produce enough testosterone. It is being studied in symptomatic late-onset hypogonadism in men aged 50 years and older. The drug is an androgen replacement therapy under clinical investigation.

Who makes testosterone undecanoate?

Testosterone undecanoate is being developed by Merck & Company, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol MRK. The company is conducting clinical research on this drug for the treatment of hypogonadism.

What phase is testosterone undecanoate in?

Testosterone undecanoate is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 2 trial has been completed to evaluate its effects in patients with symptomatic late-onset hypogonadism.

What clinical trials is testosterone undecanoate in?

Testosterone undecanoate has one completed Phase 2 clinical trial registered as NCT00434824, titled "Effects of Andriol Testocaps in Symptomatic Late-Onset Hypogonadism (43203)." This randomized, double-blind, placebo-controlled trial enrolled 322 male participants aged 50 years and older with hypogonadism.

Is testosterone undecanoate the same as Andriol Testocaps?

Yes, testosterone undecanoate is the same as Andriol Testocaps. The clinical trial NCT00434824 refers to the drug as Andriol Testocaps, which is a brand name for testosterone undecanoate. This alternative name may be used in research and clinical settings.